IMIG: Dr. Constantine Alifrangis Speaks on Next Generation Sequencing in Mesothelioma

Dr. Constantine Alifrangis focused on the study of cancer genomes and how it might be used to identify new treatments and individualize care for patients with mesothelioma. These approaches have identified specific genomic alterations in mesothelioma associated with unexpected drug sensitivities in mesothelioma. As for other cancers, study of cancer genomes in mesothelioma has the potential to guide development of novel therapies for this disease.Click here to hear and see more about this work.

Click here to watch Dr. Alifrangis’s Presentation

Related articles

• Consequences of asbestos: New laboratory installed for research into pleural cancer (workers-compensation.blogspot.com)
• How asbestos exposure leads to mesothelioma (workers-compensation.blogspot.com)
• Curcumin, special peptides boost cancer-blocking PIAS3 to neutralize cancer-activating STAT3 in mesothelioma (workers-compensation.blogspot.com)
• Novel cancer vaccine holds promise against ovarian cancer, mesothelioma (workers-compensation.blogspot.com)
• Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials (workers-compensation.blogspot.com)
• Malignant Mesothelioma Treatment (PDQ ) (workers-compensation.blogspot.com)
• Mesothelioma: New findings on treatment options (workers-compensation.blogspot.com)